--- title: "SAB Biotherapeutics Inc. Metrics Guide" description: "SAB Biotherapeutics Inc. revenue, margins, cash flow and balance sheet figures by fiscal year, taken from its SEC filings, with the ratios explained." canonical: https://www.getswoopr.com/stocks/companies/sab-biotherapeutics-inc/financial-metrics/ source: "Swoopr Investment: https://www.getswoopr.com" --- # SAB Biotherapeutics Inc. Financial Metrics Guide ## Direct Answer > SAB Biotherapeutics Inc. reported revenue of $0 for the fiscal year ended December 31, 2025, net income of $13 million, according to its SEC filings. Revenue fell 100.0% from the prior year. ## What Are SAB Biotherapeutics Inc.'s Key Financial Figures? | Fiscal year | FY2025ended December 31, 2025 | FY2024ended December 31, 2024 | FY2023ended December 31, 2023 | FY2022ended December 31, 2022 | | --- | --- | --- | --- | --- | | Revenue | $0 | $1 million | $2 million | $24 million | | Operating income | -$49 million | -$43 million | -$38 million | -$29 million | | Operating margin | n/a | -3244.9% | -1700.6% | -121.0% | | Net income | $13 million | -$34 million | -$42 million | -$19 million | | Net margin | n/a | -2579.0% | -1884.5% | -78.4% | | Operating cash flow | -$45 million | -$34 million | -$25 million | -$23 million | | Capital expenditures | $933,156 | $337,262 | $197,154 | $2 million | | Free cash flow | -$46 million | -$35 million | -$25 million | -$26 million | Free cash flow (operating cash flow minus capital expenditures) was -$46 million against net income of $13 million; cash generation fell short of reported earnings, which is worth reconciling in the cash flow statement. ![Bar chart of SAB Biotherapeutics Inc. revenue, operating income, net income for fiscal 2022 to 2025. In fiscal 2025, revenue was $0, operating income negative $49 million and net income $13 million.](https://www.getswoopr.com/images/charts/sab-biotherapeutics-inc-metrics-revenue-profit.webp) *SAB Biotherapeutics Inc. revenue, operating income and net income by fiscal year, from the figures in the table above. Select the chart to open it full size.* ![Line chart of SAB Biotherapeutics Inc. operating margin and net margin for fiscal 2022 to 2025. In fiscal 2025, operating margin was n/a and net margin was n/a.](https://www.getswoopr.com/images/charts/sab-biotherapeutics-inc-metrics-margins.webp) *SAB Biotherapeutics Inc. operating margin and net margin by fiscal year: operating income and net income as a share of revenue. Select the chart to open it full size.* ![Bar chart of SAB Biotherapeutics Inc. operating cash flow, capital expenditures, free cash flow for fiscal 2022 to 2025. In fiscal 2025, operating cash flow was negative $45 million, capital expenditures was $933,156, free cash flow was negative $46 million.](https://www.getswoopr.com/images/charts/sab-biotherapeutics-inc-metrics-cash-flow.webp) *SAB Biotherapeutics Inc. operating cash flow, capital expenditures and free cash flow by fiscal year. Select the chart to open it full size.* ## What Does SAB Biotherapeutics Inc.'s Balance Sheet Show? | Cash and cash equivalents | $11 million | | --- | --- | | Long-term debt | Not reported | | Total assets | $173 million | | Total liabilities | $21 million | | Shareholders' equity | $151 million | | Current ratio | 9.5x | Balance sheet values are as of the end of fiscal 2025. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions. ## Where These Numbers Come From Every figure on this page is a value SAB Biotherapeutics Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001833214-26-000003 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 12, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary. Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation. ## Frequently Asked Questions ### What was SAB Biotherapeutics Inc.'s revenue in fiscal 2025? SAB Biotherapeutics Inc. reported revenue of $0 for the fiscal year ended December 31, 2025, according to its SEC filings. ### What is SAB Biotherapeutics Inc.'s operating margin? SAB Biotherapeutics Inc. did not report operating income under the standard tag for fiscal 2025, so Swoopr does not compute an operating margin; the income statement in its 10-K shows how it presents profit. ### How much free cash flow did SAB Biotherapeutics Inc. generate? Operating cash flow of -$45 million less capital expenditures of $933,156 gives free cash flow of -$46 million for fiscal 2025. ## References - [SEC EDGAR: SAB Biotherapeutics, Inc. Form 10-K filed March 9, 2026](https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/sabs-20251231.htm) - [SEC EDGAR: SAB Biotherapeutics, Inc. annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1833214&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) ## Related Pages - [SAB Biotherapeutics Inc. company dossier](https://www.getswoopr.com/stocks/companies/sab-biotherapeutics-inc/) - [SAB Biotherapeutics Inc. financial metrics](https://www.getswoopr.com/stocks/companies/sab-biotherapeutics-inc/financial-metrics/) - [SAB Biotherapeutics Inc. financial risk indicators](https://www.getswoopr.com/stocks/companies/sab-biotherapeutics-inc/risks-monitoring/) - [SAB Biotherapeutics Inc. business model and revenue mix](https://www.getswoopr.com/stocks/companies/sab-biotherapeutics-inc/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) [Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/) Swoopr's editorial team produces independent investment education content. Content is for educational purposes only and does not constitute personalized investment advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).